Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line

Molecular and Cellular Endocrinology

Volumn 355, Issue 1, 2012, Pages 41-48

  Vivaldi, A ^a   Ciampi, R ^a   Tacito, A ^a   Molinaro, E ^a   Agate, L ^a   Bottici, V ^a   Pinchera, A ^a   Collecchi, P ^a   Elisei, R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Celecoxib; Chemotherapy; Medullary thyroid cancer; Tyrosine kinase inhibitors; Vinorelbine

Indexed keywords

CELECOXIB; DOXORUBICIN; GLYCOPROTEIN P; NAVELBINE; VERAPAMIL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TRANSPORT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR TRANSPORT; MULTIDRUG RESISTANCE 1 GENE; ONCOGENE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; P-GLYCOPROTEIN; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES; THYROID NEOPLASMS; VINBLASTINE;

EID: 84858748828     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.01.015     Document Type: Article

References (27)

1. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Breazna A., Kim K., Tang J., Rosenstein R.B., Umar A., Bagheri D., Collins N.T., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Hawk E.T. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. (Phila) 2009, 2:310-321.
2. Breier A., Barancik M., Sulova Z., Uhrik B. P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr. Cancer Drug Targets 2005, 5:457-468.
3. Briasoulis E., Pappas P., Puozzo C., Tolis C., Fountzilas G., Dafni U., Marselos M., Pavlidis N. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin. Cancer Res. 2009, 15:6454-6461.
4. Carlomagno F., Guida T., Anaganti S., Vecchio G., Fusco A., Ryan A.J., Billaud M., Santoro M. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004, 23:6056-6063.
5. Cohen E.E., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., Kane M.A., Sherman E., Kim S., Bycott P., Tortorici M., Shalinsky D.R., Liau K.F., Cohen R.B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol. 2008, 26:4708-4713.
6. Cui Y., Konig J., Buchholz J.K., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 1999, 55:929-937.
7. Davies N.M., McLachlan A.J., Day R.O., Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 2000, 38:225-242.
8. Doyle L.A., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22:7340-7358.
9. Falandry C., Canney P.A., Freyer G., Dirix L.Y. Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann. Oncol. 2009, 20:615-620.
10. Hoff, A.O., Hoff, P.M., 2007. Medullary thyroid carcinoma, Hematol. Oncol. Clin. North Am. 21, 475-88; viii.
11. Jaruga E., Salvioli S., Dobrucki J., Chrul S., Bandorowicz-Pikula J., Sikora E., Franceschi C., Cossarizza A., Bartosz G. Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Lett. 1998, 433:287-293.
12. Jendrossek, V., 2011. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. February 2011. [Epub ahead of print].
13. Johnstone R.W., Ruefli A.A., Smyth M.J. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem. Sci. 2000, 25:1-6.
14. Liu X., Vega Q.C., Decker R.A., Pandey A., Worby C.A., Dixon J.E. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J. Biol. Chem. 1996, 271:5309-5312.
15. Massart C., Gibassier J., Lucas C., Pourquier P., Robert J. Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil. Bull. Cancer 1996, 83:39-45.
16. Patel V.A., Dunn M.J., Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. 2002, 277:38915-38920.
17. Paulson S.K., Vaughn M.B., Jessen S.M., Lawal Y., Gresk C.J., Yan B., Maziasz T.J., Cook C.S., Karim A. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J. Pharmacol. Exp. Ther. 2001, 297:638-645.
18. Pinchera A.E.R. Medullary thyroid cancer: diagnosis and treatment. Practical Management of Thyroid Cancer 2006, 255-280. Springer-Verlag Ltd., London. E.L. Mazzaferri, C.H. Ujjal, K. Mallick, Pat Kendall-Taylor (Eds.).
19. Salgia R., Sherman S., Hong D.S., Ng C.S., Frye J., Janisch L., Ratain M.J., Kurzrock R. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J. Clin. Oncol. 2008, 26:3522.
20. Romei C., Mariotti S., Fugazzola L., Taccaliti A., Pacini F., Opocher G., Mian C., Castellano M., degli Uberti E., Ceccherini I., Cremonini N., Seregni E., Orlandi F., Ferolla P., Puxeddu E., Giorgino F., Colao A., Loli P., Bondi F., Cosci B., Bottici V., Cappai A., Pinna G., Persani L., Verga U., Boscaro M., Castagna M.G., Cappelli C., Zatelli M.C., Faggiano A., Francia G., Brandi M.L., Falchetti A., Pinchera A., Elisei R. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur. J. Endocrinol. 2010, 163:301-308.
21. Ruggeri R.M., Sciacchitano S., Vitarelli E., Trimarchi F., Barresi G., Trovato M. Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas. Arch. Pathol. Lab. Med. 2006, 130:1014-1019.
22. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55:3-29.
23. Schlumberger M.J., Elisei R., Bastholt L., Wirth L.J., Martins R.G., Locati L.D., Jarzab B., Pacini F., Daumerie C., Droz J.P., Eschenberg M.J., Sun Y.N., Juan T., Stepan D.E., Sherman S.I. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol. 2009, 27:3794-3801.
24. Stuckler D., Singhal J., Singhal S.S., Yadav S., Awasthi Y.C., Awasthi S. RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res. 2005, 65:991-998.
25. Wells S.A., Gosnell J.E., Gagel R.F., Moley J., Pfister D., Sosa J.A., Skinner M., Krebs A., Vasselli J., Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 2010, 28:767-772.
26. Zabel M., Seidel J., Kaczmarek A., Surdyk-Zasada J., Grzeszkowiak J., Gorny A. Immunocytochemical characterization of two thyroid medullary carcinoma cell lines in vitro. Histochem. J. 1995, 27:859-868.
27. Zatelli M.C., Luchin A., Piccin D., Tagliati F., Bottoni A., Vignali C., Bondanelli M., degli Uberti E.C. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 2005, 90:5754-5760.